Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia

The FDA recently approved eight targeted therapies for acute myeloid leukemia (AML), including the BCL-2 inhibitor venetoclax. Maximizing efficacy of these treatments requires refining patient selection. To this end, we analyzed two recent AML studies profiling the gene expression and ex vivo drug r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:NPJ Precis Oncol
Autors principals: White, Brian S., Khan, Suleiman A., Mason, Mike J., Ammad-ud-din, Muhammad, Potdar, Swapnil, Malani, Disha, Kuusanmäki, Heikki, Druker, Brian J., Heckman, Caroline, Kallioniemi, Olli, Kurtz, Stephen E., Porkka, Kimmo, Tognon, Cristina E., Tyner, Jeffrey W., Aittokallio, Tero, Wennerberg, Krister, Guinney, Justin
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8302655/
https://ncbi.nlm.nih.gov/pubmed/34302041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00209-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars